These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26600626)

  • 1. Analysis of the LRRK2 p.G2019S mutation in Colombian Parkinson's Disease Patients.
    Duque AF; Lopez JC; Benitez B; Hernandez H; Yunis JJ; Fernandez W; Arboleda H; Arboleda G
    Colomb Med (Cali); 2015 Sep; 46(3):117-21. PubMed ID: 26600626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
    Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
    Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
    Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
    Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lrrk2 mutations in South America: A study of Chilean Parkinson's disease.
    Perez-Pastene C; Cobb SA; Díaz-Grez F; Hulihan MM; Miranda M; Venegas P; Godoy OT; Kachergus JM; Ross OA; Layson L; Farrer MJ; Segura-Aguilar J
    Neurosci Lett; 2007 Jul; 422(3):193-7. PubMed ID: 17614198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
    Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
    Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease.
    Infante J; Rodríguez E; Combarros O; Mateo I; Fontalba A; Pascual J; Oterino A; Polo JM; Leno C; Berciano J
    Neurosci Lett; 2006 Mar; 395(3):224-6. PubMed ID: 16298482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
    Paisán-Ruíz C; Lang AE; Kawarai T; Sato C; Salehi-Rad S; Fisman GK; Al-Khairallah T; St George-Hyslop P; Singleton A; Rogaeva E
    Neurology; 2005 Sep; 65(5):696-700. PubMed ID: 16157901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant.
    Pchelina SN; Yakimovskii AF; Emelyanov AK; Ivanova ON; Schwarzman AL; Singleton AB
    Eur J Neurol; 2008 Jul; 15(7):692-6. PubMed ID: 18435766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.
    Lesage S; Janin S; Lohmann E; Leutenegger AL; Leclere L; Viallet F; Pollak P; Durif F; Thobois S; Layet V; Vidailhet M; Agid Y; Dürr A; Brice A; ; Bonnet AM; Borg M; Broussolle E; Damier P; Destée A; Martinez M; Penet C; Rasco O; Tison F; Tranchan C; Vérin M
    Arch Neurol; 2007 Mar; 64(3):425-30. PubMed ID: 17353388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features of LRRK2-associated Parkinson's disease].
    Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 mutations are a common cause of Parkinson's disease in Spain.
    Mata IF; Ross OA; Kachergus J; Huerta C; Ribacoba R; Moris G; Blazquez M; Guisasola LM; Salvador C; Martinez C; Farrer M; Alvarez V
    Eur J Neurol; 2006 Apr; 13(4):391-4. PubMed ID: 16643318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of LRRK2 mutations and Parkinson's disease in Brazil.
    Pimentel MM; Moura KC; Abdalla CB; Pereira JS; de Rosso AL; Nicaretta DH; Campos M; de Almeida RM; dos Santos JM; Bastos IC; Mendes MF; Maultasch H; Costa FH; Werneck AL; Santos-Rebouças CB
    Neurosci Lett; 2008 Mar; 433(1):17-21. PubMed ID: 18201824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease.
    Marongiu R; Ghezzi D; Ialongo T; Soleti F; Elia A; Cavone S; Albanese A; Altavista MC; Barone P; Brusa L; Cortelli P; Petrozzi L; Scaglione C; Stanzione P; Tinazzi M; Zeviani M; Dallapiccola B; Bentivoglio AR; Valente EM; Garavaglia B;
    Mov Disord; 2006 Aug; 21(8):1232-5. PubMed ID: 16622859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease.
    Yescas P; López M; Monroy N; Boll MC; Rodríguez-Violante M; Rodríguez U; Ochoa A; Alonso ME
    Neurosci Lett; 2010 Nov; 485(2):79-82. PubMed ID: 20727385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of the LRRK2 G2019S mutation in late-onset sporadic patients with Parkinson's disease.
    Chien HF; Figueiredo TR; Hollaender MA; Tofoli F; Takada LT; Pereira Lda V; Barbosa ER
    Arq Neuropsiquiatr; 2014 May; 72(5):356-9. PubMed ID: 24863511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.